🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Trupanion shares target cut on slower growth

EditorNatashya Angelica
Published 03/05/2024, 16:52
TRUP
-

On Friday, Trupanion, Inc. (NASDAQ:TRUP), a provider of medical insurance for pets, had its stock price target lowered by investment firm Piper Sandler from $28.00 to $22.00, while the stock's rating remained at Neutral.

The adjustment follows the company's recent financial performance, which showed revenue surpassing guidance but with adjusted operating income at the lower end, indicating margin pressures.

The company's subscription Pets Insurance in Force (PIF) growth for the quarter was reported to be the slowest since the first quarter of 2020. Moreover, the PIF count for other business segments experienced a decline of approximately 2.9% from the fourth quarter of 2023, after already decreasing by 2.7% in that quarter.

The current president of Trupanion is set to take over as CEO, with the founder and current CEO transitioning to the role of board chair and consultant, focusing on the company's food initiative.

Trupanion is also facing the need to incur additional expenses. These are anticipated to begin in the second quarter of 2024 to address two material weaknesses identified in the company's operations. The financial community received the news with a negative outlook, as Trupanion's shares were seen to drop by approximately 11% in after-hours trading.

Piper Sandler's maintained Neutral rating indicates a stance of watchful caution, while the reduction in the stock price target to $22 from the previous $28 reflects concerns over the company's slower growth rate. The upcoming changes in leadership and the expected costs for remediation efforts are significant developments for Trupanion as it navigates through these challenges.

InvestingPro Insights

Amidst the leadership changes and operational challenges faced by Trupanion, Inc., current financial metrics provide a mixed outlook. The company's market cap stands at a modest $965.89M, reflecting investor caution.

With a negative P/E ratio of -37.00, and an adjusted P/E ratio for the last twelve months as of Q1 2024 at -43.07, the market currently does not anticipate earnings growth in the near term. Still, revenue growth remains robust at 21.23% for the last twelve months, suggesting that Trupanion's services are still in demand.

From an operational standpoint, Trupanion's gross profit margin hovers at 18.55%, which aligns with the margin pressures indicated by Piper Sandler. Despite these pressures, analysts on InvestingPro predict the company will turn profitable this year, supported by the expectation of net income growth. Yet, investors should be aware that the stock is known for high price volatility, a factor to consider for those with a lower risk tolerance.

For those interested in a deeper dive into Trupanion's financial health, InvestingPro offers additional insights. There are 3 more InvestingPro Tips available, which can help investors make a more informed decision. To access these tips and more detailed analytics, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.